戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 al features were striking and reminiscent of diffuse Lewy body disease.
2 y bodies in sporadic Parkinson's disease and diffuse Lewy body disease.
3  absence of delusions distinguished PSP from diffuse Lewy body disease.
4 ting activity in a pattern characteristic of diffuse Lewy body disease.
5 ra of Parkinson disease and the neocortex of diffuse Lewy body disease.
6 with motor and cognitive deficits similar to diffuse Lewy body disease.
7  of PD and in brains of patients with PD and diffuse Lewy body disease.
8  mice, brains of AR-JP and idiopathic PD and diffuse Lewy body disease also exhibit increased level o
9 as Lewy body variant of Alzheimer's disease, diffuse Lewy body disease, and Parkinson's disease and s
10 In Lewy body variant of Alzheimer's disease, diffuse Lewy body disease, and Parkinson's disease, NACP
11 arkinsonism, sporadic Parkinson disease, and diffuse Lewy Body disease as well as the 1-methyl-4-phen
12 to affected regions in Parkinson disease and diffuse Lewy body disease brains.
13 comitant Alzheimer's/Parkinson's disease and diffuse Lewy body disease cases had significantly higher
14 rontotemporal degeneration (FTD) (n = 9), or diffuse Lewy body disease (DLB) with mixed AD or FTD pat
15 ological hallmark of Parkinson's disease and diffuse Lewy body disease (DLBD) is the aggregation of a
16 s isolated from postmortem human brains with diffuse Lewy body disease (DLBD) preferentially show end
17 f patients with an AD-like dementia known as diffuse Lewy-body disease (DLBD).
18 7 Lewy body variant of AD [LBVAD] and 4 pure diffuse Lewy body disease [DLBD]) who had antemortem pos
19 mpathetic output in pathologically confirmed diffuse Lewy body disease (LBD).
20               In a transgenic mouse model of diffuse Lewy body disease, long-term administration of p
21  (n = 11), Parkinson's disease (PD, n = 11), diffuse Lewy body disease (n = 14).
22 omitant Alzheimer's/Parkinson's disease, and diffuse Lewy body disease) using in situ end labeling to
23 ilon4 allele in AD subjects with concomitant diffuse Lewy body disease was intermediate between contr

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。